Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Steven D. Nathan

Inova Fairfax Hospital, Falls Church, VA

Peter Smith

United Therapeutics, Durham, NC

Chunqin Deng

United Therapeutics, Durham, NC

Christopher S. King

Inova Fairfax Hospital, Falls Church, VA

Maria De Salvo

Centro Médico Dra. De Salvo, Buenos Aires

S. Samuel Weigt

David Geffen School of Medicine at University of California, Los Angeles, Los Angeles

Sahil Pandya

University of Kansas Medical Center, Kansas City

Debabrata Bandyopadhyay

University of South Florida Health, Tampa

Joseph A. Lasky

Tulane University, New Orleans

Rachana Krishna

Medical University of South Carolina, Charleston

Nathan Hambly

Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada

Murali Ramaswamy

Pulmonix at Cone Health, Greensboro, NC

Jad Kebbe

University of Oklahoma Health Sciences Center, Oklahoma City

Neil Ettinger

Lung Research Center, Chesterfield, MO

Jamie Gao

United Therapeutics, Durham, NC

Youlan Rao

United Therapeutics, Durham, NC

Natalie Breytenbach

United Therapeutics, Durham, NC

Leigh Peterson

United Therapeutics, Durham, NC

Heidi Bell

United Therapeutics, Durham, NC

Juergen Behr

Department of Medicine V, Ludwig-Maximilians-University Munich University Hospital, Munich, Germany

Vincent Cottin

Université Claude Bernard Lyon 1, Lyon, France

Kevin R. Flaherty

Michigan Medicine, University of Michigan, Ann Arbor